01:56 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's disease. The immuno-neurology company sold 9.3 million shares at...
03:46 , Feb 7, 2019 |  BC Extra  |  Company News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) shares fell $1 to $18 Thursday after the company raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or...